查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018646

機器人切片檢查設備市場：2026-2032年全球市場預測（按產品類型、技術、手術類型、應用和最終用戶分類）

Robotic Biopsy Devices Market by Product Type, Technology, Procedure Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，機器人切片檢查設備市場價值將達到 5.1117 億美元，到 2026 年將成長至 5.7313 億美元，到 2032 年將達到 11.0661 億美元，複合年成長率為 11.66%。

主要市場統計數據
基準年 2025 5.1117億美元
預計年份：2026年 5.7313億美元
預測年份：2032年 11.0661億美元
複合年成長率 (%) 11.66%

權威概述了機器人技術、影像整合和程序創新如何融合，從而改變臨床組織採集實踐和相關人員的優先事項。

機器人切片檢查解決方案透過結合精密工程、先進成像技術和軟體主導，重新定義了臨床醫生採集組織樣本的方式，從而降低操作變異性、提高診斷可靠性並最佳化組織樣本的獲取。過去十年，微創手術與高解析度影像技術的融合，使機器人平台從小眾研究設備轉變為滿足常規診斷需求的實用臨床工具。本文概述了該技術的現狀，重點介紹了其核心臨床優勢，例如更高的靶向精度、在某些情況下更短的手術時間以及更低的併發症發生率，同時也探討了廣泛應用該技術所涉及的運營和經濟問題。

對推動機器人組織採集技術應用並重新定義競爭優勢的技術、臨床和交付模式變革進行全面分析。

在技​​術成熟、臨床需求和醫療服務模式不斷演進的推動下，機器人切片檢查設備領域正經歷著許多變革。影像引導和融合技術的進步使得針對不同解剖結構進行更精準的標靶操作成為可能，而內建軟體和機器學習技術則改進了針道規劃並補償了器官運動。這些技術進步與硬體的革新相輔相成。採用小型化、模組化架構並相容於多種成像系統的設備，降低了應用門檻，並拓展了其適用的臨床環境範圍。

對 2025 年關稅帶來的成本壓力和供應鏈調整如何重塑機器人切片檢查解決方案的採購、製造選擇和部署計劃進行實際評估。

2025年實施的關稅政策變化對研發和銷售機器人切片檢查設備的公司的供應鏈和商業策略產生了實際的影響。當進口關稅影響到關鍵零件（例如精密執行器、成像支架或專用光學元件等）時，直接後果是整套系統和耗材的總成本增加。因此，製造商和經銷商面臨多種選擇：要麼自行承擔新增成本，要麼重新分配利潤，要麼將價格上漲轉嫁給面臨降低手術成本壓力的醫療機構。

詳細的細分分析表明，產品外形規格、成像技術、臨床應用、最終用戶環境和手術類型如何決定臨床適用性和商業化路徑。

細分市場分析揭示了產品設計、影像相容性、臨床適應症、終端用戶環境和手術方法如何全面決定機器人切片檢查系統的價值所在和應用場景。不同類型的產品也對應著醫院和診所的不同應用場景。可攜式機器人最佳化了各種手術室的柔軟性，對尋求緊湊型解決方案的門診手術中心極具吸引力。機械臂提供業界級的重複性，適用於高頻次的醫院手術室；而與影像台緊密整合的桌上型機器人則支援放射科和混合手術室的精準操作。因此，技術選擇決定了工作流程和臨床表現。 CT引導系統在定位深部器官時可提供卓越的解剖訊息，而透視引導平台則可在某些介入手術中實現針頭的即時可視化。 MRI導引解決方案在軟組織對比度和前列腺定位方面表現出色，而超音波導引工具則為床邊手術提供經濟高效且無輻射的成像。

對美洲、歐洲、中東和非洲以及亞太地區的採用促進因素、監管趨勢和商業化策略進行區域展望。

區域趨勢正在影響機器人切片檢查平台的普及速度、監管政策的變化以及商業策略。在美洲，醫療機構對支持癌症早期檢測和微創診斷的創新技術表現出強勁的需求。加之完善的報銷機制加快了醫院的採購週期，美國仍然是臨床實驗室、早期採用者以及影像和介入專家緊密合作的中心。歐洲、中東和非洲的情況則更為複雜。儘管歐盟內部的監管協調一致，且各國的支付方政策有所不同，但其他次區域在基礎設施和採購實踐方面仍存在差異。這種差異為分階段產品交付以及與能夠滿足當地認證和服務交付要求的區域分銷商建立合作關係創造了機會。在亞太地區，受篩檢項目擴展、私人醫院網路發展以及對影像基礎設施的大力投資的推動，市場需求強勁。然而，成熟市場（擁有高階影像設備）與新興市場（成本意識和保守主義影響採購決策）在產品採用上存在差異。

策略競爭的重點在於夥伴關係、臨床證據、服務模式和智慧財產權優勢，這些優勢將決定機器人切片檢查解決方案的長期領導地位。

機器人切片檢查領域的競爭動態由影像設備供應商、醫療設備創新者以及能夠提供整合解決方案的相關人員之間的合作所塑造。成熟的影像設備製造商正利用其客戶關係和平台專業知識提供機器人模組，而機器人專家則專注於符合人體工學的介面、針頭控制和軟體主導。同時，敏捷的Start-Ups和學術衍生公司正推出針對特定臨床挑戰的創新技術，例如針頭操控、運動補償和人工智慧驅動的目標獲取，這迫使成熟企業透過合作、授權或收購等方式做出回應。

為了加速產品普及和保持競爭優勢，我們針對產品架構、臨床證據產生、供應鏈彈性和經營模式。

產業領導者應採取多維策略，在技術差異化和商業性現實之間取得平衡。優先考慮平台模組化，並確保其在CT引導、透視引導、MRI引導和超音波引導環境下的兼容性，將拓展可用應用範圍，並減少對多個專用底盤的需求。投資開發支援手術規劃、運動校正和決策支援的整合軟體，應能提升臨床效用，同時縮短訓練週期。同時，必須透過採購多元化、盡可能本地化組裝以及能夠緩解關稅和物流波動影響的庫存策略，來增強供應鏈的韌性。

我們採用嚴格的混合方法，結合專家訪談、監管和臨床文獻審查、專利分析和供應鏈評估，來檢驗關鍵發現。

本研究途徑結合了對臨床醫生、採購經理和技術專家的定性研究和對監管申報文件、臨床文獻以及公開醫療設備註冊資訊的系統性二手研究。透過對放射科醫生、介入醫生、護理經理和生物醫學工程團隊的訪談，我們直接了解了工作流程整合、臨床醫生偏好和採購限制等方面的見解。基於這些發現，我們提出了關於推廣障礙和價值促進因素的假設，並用二手證據檢驗。二手分析包括對同行評審的臨床研究、操作指南、監管核准摘要和專利趨勢的審查，以評估創新軌跡和底層技術的成熟度。

簡要概述了機器人切片檢查技術的臨床潛力、實施前提條件以及推廣應用所需的合作努力。

機器人切片檢查設備預計在診斷過程中發揮日益關鍵的作用，透過精準的組織取樣降低不確定性，並改善後續的臨床決策。新的技術能力，特別是影像融合、軟體主導的導航和工作流程感知的硬體設計，與醫療服務模式向微創、門診友善介入的變革性轉變相契合。然而，其廣泛應用可能取決於多種因素的綜合作用，包括針對目標適應症的可靠臨床證據、與報銷和採購流程的一致性，以及能夠降低地緣政治和關稅相關風險的穩健的生產和供應網路。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：機器人切片檢查設備市場：依產品類型分類

  • 可攜式機器人
  • 機械臂
  • 桌上型機器人

第9章：機器人切片檢查設備市場：依技術分類

  • CT引導
  • 靈媒嚮導
  • 磁共振引導
  • 超音波引導

第10章：機器人切片檢查設備市場：依手術類型分類

  • 核心針穿刺切片
  • 細針穿刺切片檢查
  • 穿刺輔助切片檢查

第11章：機器人切片檢查設備市場：按應用領域分類

  • 乳房切片
  • 切片檢查
  • 切片檢查
  • 切片檢查
  • 攝護腺切片檢查

第12章：機器人切片檢查設備市場：依最終用戶分類

  • 門診手術中心
  • 診斷中心
  • 醫院

第13章：機器人切片檢查設備市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：機器人切片檢查設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：機器人切片檢查設備市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國機器人切片檢查設備市場

第17章：中國機器人切片檢查設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Asensus Surgical, Inc.
  • Auris Health, Inc.
  • Biobot Surgical Pte Ltd
  • Brainlab AG
  • CMR Surgical Ltd.
  • Cook Medical, Inc.
  • Corindus Vascular Robotics, Inc.
  • EndoQuest Robotics, Inc.
  • Hansen Medical, Inc.
  • InnoMedicus Ltd.
  • iSYS Medizintechnik GmbH
  • Mazor Robotics
  • Medical Device Business Services, Inc.
  • Medineering GmbH
  • Medrobotics
  • Medtech SA
  • Medtronic
  • Mendaera, Inc.
  • Monteris Medical Corporation
  • Renishaw plc
  • Stereotaxis, Inc.
  • Stryker
  • TransEnterix, Inc.
  • XACT Robotics Ltd.
  • Zimmer Biomet
Product Code: MRR-221461476FC5

The Robotic Biopsy Devices Market was valued at USD 511.17 million in 2025 and is projected to grow to USD 573.13 million in 2026, with a CAGR of 11.66%, reaching USD 1,106.61 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 511.17 million
Estimated Year [2026] USD 573.13 million
Forecast Year [2032] USD 1,106.61 million
CAGR (%) 11.66%

An authoritative overview of how robotics, imaging integration, and procedural innovation are converging to transform clinical tissue sampling practices and stakeholder priorities

Robotic biopsy solutions are reshaping how clinicians obtain tissue samples, combining precision mechanics, advanced imaging, and software-driven guidance to reduce variability and improve diagnostic confidence. Over the past decade, the convergence of minimally invasive procedural techniques and high-resolution imaging modalities has enabled robotic platforms to transition from niche research instruments to practical clinical tools that address everyday diagnostic needs. This introduction frames the technology landscape by highlighting the core clinical benefits-enhanced targeting accuracy, reduced procedure times in some settings, and potential decreases in complication rates-while acknowledging the operational and economic considerations that accompany broader adoption.

Stakeholders across hospital systems, diagnostic centers, and ambulatory surgical venues are evaluating these systems through the lenses of clinical efficacy, workflow integration, and return on investment. Imaging compatibility and workflow fit are especially critical because the clinical value of a robotic biopsy device is inseparable from the imaging technology that guides it. In parallel, regulatory pathways, reimbursement environments, and clinician training requirements are evolving to keep pace with device innovation. This introduction sets the stage for a deeper exploration of technological shifts, segmentation dynamics, regional variation, and strategic levers that stakeholders can use to align product development, go-to-market, and clinical adoption strategies with the emerging realities of image-guided tissue sampling.

A comprehensive analysis of the technological, clinical, and delivery-model shifts that are driving adoption and redefining competitive advantage in robotic tissue sampling

The landscape for robotic biopsy devices is undergoing several transformative shifts driven by technological maturation, clinical demand, and changing care delivery models. Advances in imaging guidance and fusion capabilities are enabling more accurate targeting across diverse anatomies, while embedded software and machine learning are improving needle path planning and compensating for organ motion. These technical improvements are complemented by hardware evolution: smaller form factors, modular architectures, and instruments designed for compatibility with multiple imaging suites lower barriers to adoption and expand the range of viable clinical settings.

Concurrently, care delivery is decentralizing as procedures migrate from tertiary hospitals into ambulatory and outpatient environments that demand compact, cost-efficient systems. The emphasis on value-based care is incentivizing solutions that demonstrably reduce downstream costs by improving diagnostic yield and reducing repeat procedures. Supply chain and manufacturing trends are also shifting, with an emphasis on resilient sourcing and localized assembly to manage geopolitical risks. Finally, clinical acceptance is strengthening as a growing body of peer-reviewed clinical evidence and real-world experience validates the risk-benefit profile of robotic-assisted biopsies, accelerating dialogues among clinicians, payers, and health system leaders about appropriate use cases and care pathways.

A practical assessment of how tariff-driven cost pressures and supply chain adjustments in 2025 are reshaping procurement, manufacturing choices, and adoption timelines for robotic biopsy solutions

Tariff policy changes in the United States introduced in 2025 have created tangible implications for the supply chains and commercial strategies of companies developing and distributing robotic biopsy devices. When import levies affect key components-precision actuators, imaging-compatible mounts, or proprietary optics-the immediate consequence is an increase in landed cost for finished systems and consumables. Manufacturers and distributors consequently face choices about absorbing incremental costs, reallocating margin, or passing increases to institutional buyers who are themselves under pressure to control procedural expenditures.

In response, several strategic adjustments have become common. Suppliers are reassessing procurement strategies and exploring nearshoring or expanded local assembly to reduce exposure to tariffs and transit disruptions. Contracting practices with hospital systems and diagnostic providers now more frequently include clauses that address input-cost volatility and inventory buffers. For smaller innovators, elevated import costs have tightened runway and increased the importance of strategic partnerships or licensing arrangements with established manufacturers that can offer scale and more diversified sourcing. Ultimately, tariff-driven cost effects slow some purchasing cycles and intensify emphasis on total cost of ownership, which certifies that stakeholder decisions now weigh both clinical performance and procurement resilience in evaluating new robotic biopsy platforms.

In-depth segmentation analysis showing how product form factor, imaging technology, clinical application, end-user environment, and procedure type determine clinical fit and commercialization pathways

Segmentation insights reveal how product design, imaging compatibility, clinical indication, end-user environment, and procedural technique collectively determine where and how robotic biopsy systems deliver value. Differences in product type create distinct hospital and clinic use cases; Portable Robots are optimized for flexibility across procedure rooms and are attractive to ambulatory surgical centers seeking compact solutions, Robotic Arms offer industrial-grade repeatability suited to high-volume hospital suites, and Table Mounted Robots integrate tightly with imaging tables to support precision work in radiology and hybrid operating rooms. Correspondingly, technology choices dictate workflow and clinical performance: CT Guided systems deliver excellent anatomical context for deeper organ targets, Fluoroscopy Guided platforms enable real-time needle visualization for specific interventional procedures, MRI Guided solutions excel in soft-tissue contrast and prostate localization, and Ultrasound Guided tools offer cost-effective, radiation-free imaging for bedside interventions.

Clinical application segmentation highlights the diversity of use cases and procedural complexity. Breast Biopsy procedures often prioritize speed and patient comfort, Kidney Biopsy requires precise depth control in a moving organ, Liver Biopsy balances access paths with bleeding risk, Lung Biopsy demands navigation through respiratory motion and complex thoracic anatomy, and Prostate Biopsy benefits from MRI fusion and enhanced targeting accuracy. End-user segmentation clarifies deployment dynamics: Ambulatory Surgical Centers prioritize portability and rapid turnover, Diagnostic Centers emphasize throughput and integration with existing imaging workflows, and Hospitals require versatility, sterilization pathways, and comprehensive service agreements. Procedure type further influences device design and consumable strategies; Core Needle Biopsy favors robust sampling mechanics for tissue cores, Fine Needle Aspiration demands delicate needle control and cytology-focused handling, and Vacuum Assisted Biopsy necessitates integration with aspirating mechanisms and specimen management systems. Together, these segmentation perspectives guide product roadmaps, clinical validation plans, and sales motions to ensure alignment with real-world procedural needs.

A regional perspective on adoption drivers, regulatory dynamics, and commercialization strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape adoption velocity, regulatory trajectories, and commercial strategies for robotic biopsy platforms. In the Americas, health systems exhibit strong demand for innovation that supports early cancer detection and minimally invasive diagnostics, paired with well-established reimbursement frameworks that expedite hospital procurement cycles; the United States remains a focal point for clinical trials, early adopter institutions, and a dense network of imaging and interventional specialists. Europe, Middle East & Africa present a more heterogeneous landscape where regulatory harmonization across the European Union and national payer policies coexist with variable infrastructure and procurement practices in other subregions; this diversity creates opportunities for tiered product offerings and partnerships with regional distributors that can manage local certification and service delivery requirements. Asia-Pacific demonstrates robust demand driven by growing screening programs, expanding private hospital networks, and proactive investments in imaging infrastructure, but adoption nuances differ between mature markets with high-end imaging suites and emerging markets where cost sensitivity and serviceability shape procurement decisions.

Across all regions, clinical evidence generation, localized service capabilities, and supply chain resilience are critical determinants of sustained adoption. Regional regulatory timelines influence product launch sequencing, while training and education programs tailored to local clinical workflows accelerate clinician acceptance. Manufacturers and distributors therefore prioritize region-specific commercialization strategies that reflect differences in payer incentives, hospital procurement cycles, and the distribution networks required to support long-term device uptime and consumable supply.

Strategic competitive dynamics emphasizing partnerships, clinical evidence, service models, and intellectual property advantages that determine long-term leadership in robotic biopsy solutions

Competitive dynamics in the robotic biopsy domain are shaped by alliances between imaging providers, device innovators, and clinical stakeholders that can deliver integrated solutions. Established imaging manufacturers are leveraging their customer relationships and platform expertise to offer robotics-compatible modules, while pure-play robotics firms concentrate on ergonomic interfaces, needle control, and software-driven guidance. At the same time, agile startups and academic spin-offs introduce focused innovations-needle steering, motion compensation, and AI-supported targeting-that address specific clinical pain points and compel incumbents to respond through collaboration, licensing, or acquisition.

Commercial success hinges on the ability to demonstrate clinical value and to implement scalable service models. Organizations that combine robust clinical evidence with comprehensive aftermarket support, consumable supply chains, and training services tend to achieve faster penetration in hospital systems and diagnostic networks. Intellectual property positions and regulatory experience also create barriers that favor players with established compliance teams and clinical trial capabilities. Ultimately, the competitive landscape rewards firms that can align engineering excellence with pragmatic commercialization tactics-crossing the gap from promising prototypes to devices that integrate seamlessly into daily clinical workflows and institutional procurement processes.

Actionable strategic recommendations for product architecture, clinical evidence generation, supply resilience, and commercial models to accelerate adoption and sustain competitive differentiation

Industry leaders should adopt a multi-dimensional strategy that balances technological differentiation with commercial pragmatism. Prioritize platform modularity to enable compatibility across CT Guided, Fluoroscopy Guided, MRI Guided, and Ultrasound Guided environments, which increases addressable use cases and reduces the need for multiple, specialized chassis. Invest in integrated software that supports procedural planning, motion compensation, and decision support to raise clinical utility while shortening training curves. At the same time, strengthen supply chain resilience through diversified sourcing, localized assembly where feasible, and inventory strategies that mitigate tariff and logistics volatility.

Commercial strategies should emphasize evidence-based value communication. Develop targeted clinical studies across prioritized applications-such as Lung Biopsy and Prostate Biopsy-while creating proof points for settings including Ambulatory Surgical Centers and Diagnostic Centers. Offer flexible acquisition options, including leasing and pay-per-use models, to lower initial capital barriers for outpatient facilities. Collaborate with imaging manufacturers and health system partners to co-develop validated workflows that demonstrate reductions in repeat procedures or improved diagnostic yield. Finally, invest in scalable training programs and remote support capabilities so clinical teams can adopt new technologies with confidence, thereby accelerating uptake and realizing the procedural efficiencies these systems promise.

A rigorous mixed-methods research approach combining expert interviews, regulatory and clinical literature review, patent analysis, and supply chain assessment to validate key insights

The research approach combines primary qualitative engagement with clinicians, procurement leaders, and technical experts alongside a systematic secondary review of regulatory filings, clinical literature, and publicly available device registries. Primary interviews provided first-hand perspectives on workflow integration, clinician preferences, and procurement constraints from radiologists, interventionalists, nursing leadership, and biomedical engineering teams. These engagements informed hypotheses about adoption barriers and value drivers that were then tested against secondary evidence. Secondary analysis included a review of peer-reviewed clinical studies, procedural guidelines, regulatory clearance summaries, and patent landscapes to assess innovation trajectories and the maturity of enabling technologies.

Supplementing qualitative insights, supply chain and commercial analyses examined supplier concentration, component criticality, and procurement practices across hospital systems and outpatient facilities. Reimbursement and policy reviews were conducted to understand payer incentives and billing mechanisms that affect procedural economics. Where possible, triangulation across data sources validated trends and provided a robust foundation for the strategic recommendations presented. The methodology prioritizes transparency and reproducibility by documenting interview protocols, inclusion criteria for secondary sources, and analytic frameworks used to synthesize clinical, technical, and commercial findings.

A concise concluding synthesis emphasizing the clinical promise, adoption prerequisites, and coordinated actions required to mainstream robotic biopsy technologies

Robotic biopsy devices are poised to play an increasingly important role in diagnostic pathways where precision tissue sampling reduces uncertainty and improves downstream clinical decision-making. Emerging technical capabilities-particularly in imaging integration, software-driven guidance, and workflow-friendly hardware designs-are aligning with shifts in care delivery that favor minimally invasive, outpatient-friendly interventions. However, broader adoption will depend on a confluence of factors: credible clinical evidence across targeted applications, alignment with reimbursement and procurement practices, and resilient manufacturing and supply networks that mitigate geopolitical and tariff-related risks.

For stakeholders, the path forward involves coordinated investment in clinical validation, purposeful partnerships with imaging and service providers, and flexible commercial models that address the capital constraints of a diverse set of end users. When these elements come together, robotic biopsy platforms can deliver measurable improvements in diagnostic performance and patient experience. As the technology ecosystem matures, organizations that combine operational rigor with clinical empathy will lead the transition from experimental adoption to routine procedural practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Robotic Biopsy Devices Market, by Product Type

  • 8.1. Portable Robots
  • 8.2. Robotic Arms
  • 8.3. Table Mounted Robots

9. Robotic Biopsy Devices Market, by Technology

  • 9.1. CT Guided
  • 9.2. Fluoroscopy Guided
  • 9.3. MRI Guided
  • 9.4. Ultrasound Guided

10. Robotic Biopsy Devices Market, by Procedure Type

  • 10.1. Core Needle Biopsy
  • 10.2. Fine Needle Aspiration
  • 10.3. Vacuum Assisted Biopsy

11. Robotic Biopsy Devices Market, by Application

  • 11.1. Breast Biopsy
  • 11.2. Kidney Biopsy
  • 11.3. Liver Biopsy
  • 11.4. Lung Biopsy
  • 11.5. Prostate Biopsy

12. Robotic Biopsy Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals

13. Robotic Biopsy Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Robotic Biopsy Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Robotic Biopsy Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Robotic Biopsy Devices Market

17. China Robotic Biopsy Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Asensus Surgical, Inc.
  • 18.6. Auris Health, Inc.
  • 18.7. Biobot Surgical Pte Ltd
  • 18.8. Brainlab AG
  • 18.9. CMR Surgical Ltd.
  • 18.10. Cook Medical, Inc.
  • 18.11. Corindus Vascular Robotics, Inc.
  • 18.12. EndoQuest Robotics, Inc.
  • 18.13. Hansen Medical, Inc.
  • 18.14. InnoMedicus Ltd.
  • 18.15. iSYS Medizintechnik GmbH
  • 18.16. Mazor Robotics
  • 18.17. Medical Device Business Services, Inc.
  • 18.18. Medineering GmbH
  • 18.19. Medrobotics
  • 18.20. Medtech SA
  • 18.21. Medtronic
  • 18.22. Mendaera, Inc.
  • 18.23. Monteris Medical Corporation
  • 18.24. Renishaw plc
  • 18.25. Stereotaxis, Inc.
  • 18.26. Stryker
  • 18.27. TransEnterix, Inc.
  • 18.28. XACT Robotics Ltd.
  • 18.29. Zimmer Biomet

LIST OF FIGURES

  • FIGURE 1. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ROBOTIC BIOPSY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ROBOTIC BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ROBOTIC BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PORTABLE ROBOTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PORTABLE ROBOTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PORTABLE ROBOTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY ROBOTIC ARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY ROBOTIC ARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY ROBOTIC ARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TABLE MOUNTED ROBOTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TABLE MOUNTED ROBOTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TABLE MOUNTED ROBOTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY CT GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY CT GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY CT GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY FLUOROSCOPY GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY FLUOROSCOPY GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY FLUOROSCOPY GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY MRI GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY MRI GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY MRI GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY ULTRASOUND GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY ULTRASOUND GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY ULTRASOUND GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY BREAST BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY BREAST BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY BREAST BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY KIDNEY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY KIDNEY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY LIVER BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY LIVER BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY LIVER BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY LUNG BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY LUNG BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY LUNG BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROSTATE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROSTATE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROSTATE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ROBOTIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES ROBOTIC BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA ROBOTIC BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ROBOTIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)